Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.
Cosman, Felicia; Miller, Paul D; Williams, Gregory C; Hattersley, Gary; Hu, Ming-Yi; Valter, Ivo; Fitzpatrick, Lorraine A; Riis, Bente Juel; Christiansen, Claus; Bilezikian, John P; Black, Dennis.
Mayo Clin Proc
; 92(2): 200-210, 2017 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-28160873
Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34).
Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis.
Abaloparatide for the treatment of postmenopausal osteoporosis.
Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis.
Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis.
Parathyroid Hormone-Related Protein Analogs as Osteoporosis Therapies.
Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.
Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy.
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.